Accelerated tumor growth mediated by sublytic levels of antibody-induced complement activation is associated with activation of the PI3K/AKT survival pathway

Clinical Cancer Research

Volumn 19, Issue 17, 2013, Pages 4728-4739

  Wu, Xiaohong ^a   Ragupathi, Govind ^a   Panageas, Katherine ^a   Hong, Feng ^a   Livingston, Philip O ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MabVax Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; CD20 ANTIGEN; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GM2; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RITUXIMAB; WORTMANNIN;

ARTICLE; CELL CULTURE; COMPLEMENT ACTIVATION; DRUG EFFICACY; ENZYME ACTIVATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROLOGY; TUMOR GROWTH;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTIGENS, SURFACE; CELL LINE, TUMOR; COMPLEMENT ACTIVATION; GANGLIOSIDES; GANGLIOSIDOSES, GM2; HUMANS; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84883482466     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0088     Document Type: Article

References (41)

1. Svennerholm L. Chromatographic separation of human brain gangliosides. J Neurochem 1963;10:613-23.
2. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, et al. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A 1985;82:1242-6. (Pubitemid 15100531)
3. Imai M, Landen C, Ohta R, Cheung NK, Tomlinson S. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res 2005;65:10562-8. (Pubitemid 41743751)
4. Irie RF, Matsuki T, Morton DL. Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1989;1:786-7. (Pubitemid 19093513)
5. Kushner BH, Kramer K, Cheung NK. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001;19:4189-94. (Pubitemid 33081635)
6. Nasi ML, Meyers M, Livingston PO, Houghton AN, Chapman PB. Antimelanoma effects of R24, a monoclonal antibody against GD3 ganglioside. Melanoma Res 1997;7 Suppl 2:S155-62. (Pubitemid 27501641)
7. Retter MW, Johnson JC, Peckham DW, Bannink JE, Bangur CS, Dresser K, et al. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts. Cancer Res 2005;65:6425-34. (Pubitemid 40994431)
8. Zhang H, Zhang S, Cheung NK, Ragupathi G, Livingston PO. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases.Cancer Res 1998;58:2844-9. (Pubitemid 28311917)
9. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80. (Pubitemid 32391207)
10. Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM. Prognostic signi ficance of serum S100B protein in high-risk surgically resected melanoma patients participating in intergroup trial ECOG 1694. J Clin Oncol 2009;27:38-44.
11. Eggermont A. EORTC 18961: post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results. J Clin Oncol 26:15s, 2008 (suppl; abstr 9004).
12. Eggermont A, Suciu S, Ruka W, Marsden J, Testori A, Corrie P, et al. Randomized phase III trial comparing post-operative adjuvant ganglioside GM2-KLH-QS 21 vaccination treatment vs. observation in stage II (T3-T4N0M0) melanoma: final results of the EORTC 18961 study. J Clin Oncol 28:15s, 2010 (suppl; abstr 8505).
13. Hamilton WB, Helling F, Lloyd KO, Livingston PO. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer 1993;53:566-73. (Pubitemid 23069265)
14. Tsuchida T, Saxton RE, Morton DL, Irie RF. Gangliosides of human melanoma. Cancer 1989;63:1166-74. (Pubitemid 19074749)
15. Zhang S, Helling F, Lloyd KO, Livingston PO. Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides. Cancer Immunol Immunother 1995;40:88-94.
16. Halperin JA, Taratuska A, Nicholson-Weller A. Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest 1993;91:1974-8. (Pubitemid 23141468)
17. Reiter Y, Ciobotariu A, Fishelson Z. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. Eur J Immunol 1992;22:1207-13.
18. Rus HG, Niculescu FI, Shin ML. Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol Rev 2001;180:49-55. (Pubitemid 32472851)
19. Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 1985;45:2642-9. (Pubitemid 15024436)
20. Dippold WG, Dienes HP, Knuth A, Meyer zum Buschenfelde KH. Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors, and normal tissues. Cancer Res 1985;45:3699-705. (Pubitemid 15226447)
21. Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998;58:5396-405. (Pubitemid 28551122)
22. Keshelava N, Groshen S, Reynolds CP. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother Pharmacol 2000;45:1-8. (Pubitemid 30099708)
23. Cheung NK, Modak S. Oral (1->3),(1->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res 2002;8:1217-23. (Pubitemid 34517661)
24. Modak S, Koehne G, Vickers A, O'Reilly RJ, Cheung NK. Rituximab therapy of lymphoma is enhanced by orally administered (1->3),(1->4)-D-beta- glucan. Leuk Res 2005;29:679-83. (Pubitemid 40603569)
25. Livingston PO, Hood C, Krug LM, Warren N, Kris MG, Brezicka T, et al. Selection of GM2, fucosyl GM1, globo H, and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy. Cancer Immunol Immunother 2005;54:1018-25. (Pubitemid 41187710)
26. Ragupathi G, Liu NX, Musselli C, Powell S, Lloyd K, Livingston PO. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J Immunol 2005;174:5706-12. (Pubitemid 40593213)
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
28. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29:917-24.
29. Disis ML. Immune regulation of cancer. J Clin Oncol 2010;28:4531-8.
30. Shearer WT, Parker CW. Antibody and complement modulation of tumor cell growth in vitro and in vivo. Fed Proc 1978;37:2385-9. (Pubitemid 8399812)
31. Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008;13:954-66.
32. Livingston PO, Ragupathi G. Gangliosides as targets for cancer immunotherapy. In: Encyclopedia of cancer targets reference book: Editor-in-chief:Marshall John LCo-editorsLou Weiner, Edward Gelmann, Howard Kaufman, Anton Wellstein; 2013, In Press.
33. Hedlund M, Padler-Karavani V, Varki NM, Varki A. Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression. Proc Natl Acad Sci U S A 2008;105:18936-41.
34. Padler-Karavani V, Hurtado-Ziola N, Pu M, Yu H, Huang S, Muthana S, et al. Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. Cancer Res 2011;71:3352-63.
35. Nguyen DH, Tangvoranuntakul P, Varki A. Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells. J Immunol 2005;175:228-36. (Pubitemid 40884323)
36. Markiewski MM, DeAngelis RA, Lambris JD. Complexity of complement activation in sepsis. J Cell Mol Med 2008;12:2245-54.
37. Wang L, Halliday D, Johnson PM, Christmas SE. Expression of complement regulatory proteins on human natural killer cell subsets. Immunol Lett 2007;112:104-9. (Pubitemid 47379854)
38. Stoiber H, Soederholm A, Wilflingseder D, Gusenbauer S, Hildgartner A, Dierich MP. Complement and antibodies: a dangerous liaison in HIV infection? Vaccine 2008;26 Suppl 8:I79-85.
39. Chen Y, Zhang J, Guo G, Ruan Z, Jiang M, Wu S, et al. Induced B7-H1 expression on human renal tubular epithelial cells by the sublytic terminal complement complex C5b-9. Mol Immunol 2009;46:375-83.
40. Fosbrink M, Niculescu F, Rus H. The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription. Immunol Res 2005;31:37-46. (Pubitemid 40065423)
41. Gao L, Qiu W, Wang Y, Xu W, Xu J, Tong J. Sublytic complement C5b-9 complexes induce thrombospondin-1 production in rat glomerular mesangial cells via PI3-k/Akt: association with activation of latent transforming growth factor-beta1. Clin Exp Immunol 2006;144:326-34.